Theralase Technologies Inc (TLTFF)

[RWC2587]

TORONTO, ON / ACCESSWIRE / July 16, 2015 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSX VENTURE: TLT) (TLTFF), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has appointed Michael Borovec as the Director of Investor Relations for the Company.

Michael possesses over 10 years' experience in investor relations and capital markets. He successfully completed the Canadian Securities Course, as well as his Series 7, 22 and 63 US licences in 2001. Michael graduated with a Business Management degree from Humber College in 1999 and an International Politics degree from York University in 2005.

Roger Dumoulin-White, President and CEO, Theralase stated, "Michael has a strong working knowledge of the financial markets, security regulations and investor relations, with a demonstrated track record in serving as a corporate spokesman in the investor community. Michael's main role with the organization will be to provide strategic corporate updates to the investment community, on a timely basis, in order to provide investors with the latest news about Theralase and our opportunities for growth. Michael will also be responsible for laying the groundwork for the Company to graduate to the Toronto Stock Exchange and eventually the NASDAQ stock exchange.